Sun Pharma to acquire Organon for $11.75B in innovative shift

Sun Pharmaceutical Industries has entered into a definitive agreement to acquire Organon (NYSE:OGN) in an all-cash transaction valued at $11.75 billion, a move that propels the Indian multinational into the top tier of global pharmaceutical players and secures a leading position in the women’s health sector.

The Mumbai-based Sun Pharma will pay $14 per share for all outstanding shares of Organon, representing a strategic pivot toward innovative medicines and high-growth biosimilars.

The acquisition values Organon, which was spun off from Merck in 2021, at an enterprise valuation that underscores its significant global reach.

The transaction has already received approval from the boards of directors of both companies and remains subject to regulatory clearances and the approval of Organon stockholders.

The merger combines Sun Pharma’s robust manufacturing capabilities with Organon’s portfolio of more than 70 products focused on Women’s Health and General Medicines.

Upon completion, the combined entity is expected to generate annual revenue of approximately $12.4 billion, placing it among the top 25 pharmaceutical companies worldwide.

This growth is aligned with Sun Pharma’s long-term strategy to expand its Innovative Medicines business, which is projected to account for 27% of the combined company's total revenue.

Beyond scale, the deal transforms Sun Pharma’s competitive standing in several high-value therapeutic areas.